Home > Boards > US OTC > Biotechs > Cytodyn Inc. (CYDY)

https://en.wikipedia.org/wiki/Data_monitoring_committee>>> Overwhelming benefit

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
ombowstring Member Profile
 
Followed By 16
Posts 3,494
Boards Moderated 0
Alias Born 09/27/05
160x600 placeholder
Current Report Filing (8-k) Edgar (US Regulatory) - 7/31/2020 5:21:59 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/24/2020 4:34:37 PM
Additional Proxy Soliciting Materials (definitive) (defa14a) Edgar (US Regulatory) - 7/8/2020 5:07:43 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 7/8/2020 4:31:38 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/19/2020 5:19:36 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 6/8/2020 7:24:49 PM
Proxy Soliciting Materials (revised) (prer14a) Edgar (US Regulatory) - 6/8/2020 5:28:53 PM
Proxy Statement - Notice of Shareholders Meeting (preliminary) (pre 14a) Edgar (US Regulatory) - 6/8/2020 6:02:50 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 6/2/2020 5:01:56 PM
Amended Current Report Filing (8-k/a) Edgar (US Regulatory) - 6/2/2020 8:01:17 AM
Amended Statement of Changes in Beneficial Ownership (4/a) Edgar (US Regulatory) - 5/15/2020 8:47:08 AM
Notice of Effectiveness (effect) Edgar (US Regulatory) - 5/12/2020 6:00:59 AM
Securities Registration Statement (simplified Form) (s-3/a) Edgar (US Regulatory) - 4/30/2020 5:28:39 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/28/2020 5:29:47 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/27/2020 5:03:47 PM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/23/2020 5:08:55 PM
Amended Statement of Beneficial Ownership (3/a) Edgar (US Regulatory) - 4/22/2020 7:35:43 PM
Statement of Changes in Beneficial Ownership (4) Edgar (US Regulatory) - 4/22/2020 5:38:33 PM
Initial Statement of Beneficial Ownership (3) Edgar (US Regulatory) - 4/22/2020 5:16:18 PM
The Next Hot Sector is Upon us and You Will Never Guess What It is InvestorsHub NewsWire - 4/16/2020 8:00:00 AM
Quarterly Report (10-q) Edgar (US Regulatory) - 4/9/2020 4:45:19 PM
Other Filing Edgar (US Regulatory) - 4/9/2020 10:24:51 AM
Other Filing Edgar (US Regulatory) - 4/9/2020 10:24:21 AM
Amended Small Company Offering and Sale of Securities Without Registration (d/a) Edgar (US Regulatory) - 4/7/2020 10:48:57 AM
Current Report Filing (8-k) Edgar (US Regulatory) - 4/6/2020 5:06:53 PM
ombowstring   Wednesday, 07/15/20 12:13:04 PM
Re: None
Post # of 103078 
https://en.wikipedia.org/wiki/Data_monitoring_committee

>>> Overwhelming benefit

In the fortunate situation that the experimental arm is shown to be undeniably superior to the control arm the DMC may recommend termination of the trial. This would allow the company sponsoring the trial to get regulatory approval earlier and to allow the superior treatment to get to the patient population earlier. There are cautions here though. The statistical evidence needs to be very high indeed.[citation needed] Also, there might be other reasons to continue, such as collecting more long-term safety data. <<<

If the committee lives up to its responsibilty, leronlimab should be a cinch to get FDA approval.

Public Reply | Private Reply | Keep | Last ReadPost New MsgNext 10 | Previous | Next
Follow Board Follow Board Keyboard Shortcuts Report TOS Violation
X
Current Price
Change
Volume
Detailed Quote - Discussion Board
Intraday Chart
+/- to Watchlist